Androgen replacement therapy in women

References

• Arlt W. Androgen therapy in women. Eur. J. Endocrinol. 154(1), 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog. Brain Res. 182, 97–148 (2010).
   PubMed Web of Science ®Google Scholar
• Longscope C. Dehydroepiandrosterone metabolism. J. Endocrinol. 150, S125 (1996).
   Web of Science ®Google Scholar
• Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126(2), 1165–1172 (1990).
   PubMed Web of Science ®Google Scholar
• Hammer F, Subtil S, Lux P et al. No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 90(6), 3600–3605 (2005).
   PubMed Web of Science ®Google Scholar
• Arlt W, Justl HG, Callies F et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J. Clin. Endocrinol. Metab. 83(6), 1928–1934 (1998).
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Hornsby PJ, Casson P et al. Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. J. Clin. Endocrinol. Metab. 94(6), 2192–2198 (2009).
   PubMed Web of Science ®Google Scholar
• Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 18(1), 30–43 (2011).
   PubMed Web of Science ®Google Scholar
• Adashi EY. The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil. Steril. 62, 20–27 (1994).
   PubMed Web of Science ®Google Scholar
• Judd HL, Judd GE, Lucas WE, Yen SS. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol. Metab. 39(6), 1020–1024 (1974).
   PubMed Web of Science ®Google Scholar
• Idkowiak J, Lavery GG, Dhir V et al. Premature adrenarche: novel lessons from early onset androgen excess. Eur. J. Endocrinol. 165(2), 189–207 (2011).
   PubMed Web of Science ®Google Scholar
• Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab. 90(7), 3847–3853 (2005).
   PubMed Web of Science ®Google Scholar
• Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59(3), 551–555 (1984).
   PubMed Web of Science ®Google Scholar
• Spencer JB, Klein M, Kumar A, Azziz R. The age-associated decline of androgens in reproductive age and menopausal Black and White women. J. Clin. Endocrinol. Metab. 92(12), 4730–4733 (2007).
   PubMed Web of Science ®Google Scholar
• Arlt W. Dehydroepiandrosterone and ageing. Best Pract. Res. Clin. Endocrinol. Metab. 18(3), 363–380 (2004).
   PubMed Web of Science ®Google Scholar
• De Gendt K, Verhoeven G. Tissue- and cell-specific functions of the androgen receptor revealed through conditional knockout models in mice. Mol. Cell. Endocrinol. 352(1–2), 13–25 (2012).
   PubMed Web of Science ®Google Scholar
• Walters KA, Allan CM, Handelsman DJ. Androgen actions and the ovary. Biol. Reprod. 78(3), 380–389 (2008).
   PubMed Web of Science ®Google Scholar
• Bancroft J. Sexual effects of androgens in women: some theoretical considerations. Fertil. Steril. 77(Suppl. 4), S55–S59 (2002).
   PubMed Web of Science ®Google Scholar
• Sarrel PM. Psychosexual effects of menopause: role of androgens. Am. J. Obstet. Gynecol. 180(3 Pt 2), S319–S324 (1999).
   PubMed Web of Science ®Google Scholar
• Ebinger M, Sievers C, Ivan D, Schneider HJ, Stalla GK. Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression? J. Psychopharmacol. (Oxford) 23(7), 841–853 (2009).
   PubMed Web of Science ®Google Scholar
• Rosner W, Vesper H; Endocrine Society; American Association for Clinical Chemistry; American Association of Clinical Endocrinologists; Androgen Excess/PCOS Society; American Society for Bone and Mineral Research; American Society for Reproductive Medicine; American Urological Association; Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society. Toward excellence in testosterone testing: a consensus statement. J. Clin. Endocrinol. Metab. 95(10), 4542–4548 (2010).
   PubMed Web of Science ®Google Scholar
• Janse F, Eijkemans MJ, Goverde AJ et al. Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. Eur. J. Endocrinol. 165(6), 925–933 (2011).
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ. Measurement of androgens in women. Semin. Reprod. Med. 24(2), 78–85 (2006).
   PubMed Web of Science ®Google Scholar
• Kushnir MM, Blamires T, Rockwood AL et al. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin. Chem. 56(7), 1138–1147 (2010).
   PubMed Web of Science ®Google Scholar
• Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 53(1), 58–68 (1981).
   PubMed Web of Science ®Google Scholar
• Mendel CM. The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J. Androl. 13(2), 107–116 (1992).
   PubMedGoogle Scholar
• Emadi-Konjin P, Bain J, Bromberg IL. Evaluation of an algorithm for calculation of serum “bioavailable” testosterone (BAT). Clin. Biochem. 36(8), 591–596 (2003).
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bancroft J, Braunstein G et al. Princeton. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil. Steril. 77(4), 660–665 (2002).
   PubMed Web of Science ®Google Scholar
• Burger HG, Papalia MA. A clinical update on female androgen insufficiency – testosterone testing and treatment in women presenting with low sexual desire. Sex. Health 3(2), 73–78 (2006).
   PubMedGoogle Scholar
• Basson R, Berman J, Burnett A et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J. Urol. 163(3), 888–893 (2000).
   PubMed Web of Science ®Google Scholar
• Geiss IM, Umek WH, Dungl A, Sam C, Riss P, Hanzal E. Prevalence of female sexual dysfunction in gynecologic and urogynecologic patients according to the international consensus classification. Urology 62(3), 514–518 (2003).
   PubMed Web of Science ®Google Scholar
• Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281(6), 537–544 (1999).
   PubMed Web of Science ®Google Scholar
• Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 294(1), 91–96 (2005).
   PubMed Web of Science ®Google Scholar
• Wierman ME, Basson R, Davis SR et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J. Clin. Endocrinol. Metab. 91(10), 3697–3710 (2006).
   PubMed Web of Science ®Google Scholar
• Judd HL. Hormonal dynamics associated with the menopause. Clin. Obstet. Gynecol. 19(4), 775–788 (1976).
   PubMedGoogle Scholar
• Nathorst-Böös J, von Schoultz B. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol. Obstet. Invest. 34(2), 97–101 (1992).
   PubMed Web of Science ®Google Scholar
• Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343(10), 682–688 (2000).
   PubMed Web of Science ®Google Scholar
• Buster JE, Kingsberg SA, Aguirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol. 105(5 Pt 1), 944–952 (2005).
   PubMed Web of Science ®Google Scholar
• Simon J, Braunstein G, Nachtigall L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J. Clin. Endocrinol. Metab. 90(9), 5226–5233 (2005).
   PubMed Web of Science ®Google Scholar
• Arlt W. Androgen replacement therapy in women. Curr. Opin. Investig. Drugs 6(10), 1028–1036 (2005).
   PubMedGoogle Scholar
• Davis SR, Moreau M, Kroll R et al. APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med. 359(19), 2005–2017 (2008).
   PubMed Web of Science ®Google Scholar
• Panay N, Al-Azzawi F, Bouchard C et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 13(2), 121–131 (2010).
   PubMed Web of Science ®Google Scholar
• Penteado SR, Fonseca AM, Bagnoli VR, Abdo CH, Júnior JM, Baracat EC. Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. Climacteric 11(1), 17–25 (2008).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Young R, Notelovitz M et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J. Reprod. Med. 44(12), 1012–1020 (1999).
   PubMed Web of Science ®Google Scholar
• Braunstein GD, Sundwall DA, Katz M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch. Intern. Med. 165(14), 1582–1589 (2005).
   PubMed Web of Science ®Google Scholar
• Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin. Endocrinol. (Oxf) 57(2), 209–214 (2002).
   PubMed Web of Science ®Google Scholar
• Chiuve SE, Martin LA, Campos H, Sacks FM. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. J. Clin. Endocrinol. Metab. 89(5), 2207–2213 (2004).
   PubMed Web of Science ®Google Scholar
• Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas 21(3), 227–236 (1995).
   PubMed Web of Science ®Google Scholar
• Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 7(6), 395–401 (2000).
   PubMed Web of Science ®Google Scholar
• Davis SR, van der Mooren MJ, van Lunsen RH et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 13(3), 387–396 (2006).
   PubMed Web of Science ®Google Scholar
• Davis SR, Hirschberg AL, Wagner LK, Lodhi I, von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J. Clin. Endocrinol. Metab. 94(12), 4907–4913 (2009).
   PubMed Web of Science ®Google Scholar
• de Paula FJ, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Maturitas 56(1), 69–77 (2007).
   PubMed Web of Science ®Google Scholar
• Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J. Clin. Endocrinol. Metab. 87(4), 1509–1516 (2002).
   PubMed Web of Science ®Google Scholar
• El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 10(4), 335–343 (2007).
   PubMed Web of Science ®Google Scholar
• Flöter A, Nathorst-Böös J, Carlström K, Ohlsson C, Ringertz H, Schoultz B. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. Gynecol. Endocrinol. 20(3), 155–160 (2005).
   PubMed Web of Science ®Google Scholar
• Nathorst-Böös J, Jarkander-Rolff M, Carlström K, Flöter A, von Schoultz B. Percutaneous administration of testosterone gel in postmenopausal women – a pharmacological study. Gynecol. Endocrinol. 20(5), 243–248 (2005).
   PubMed Web of Science ®Google Scholar
• Hofling M, Lundström E, Azavedo E, Svane G, Hirschberg AL, von Schoultz B. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. Climacteric 10(2), 155–163 (2007).
   PubMed Web of Science ®Google Scholar
• Hofling M, Hirschberg AL, Skoog L, Tani E, Hägerström T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 14(2), 183–190 (2007).
   PubMed Web of Science ®Google Scholar
• Penotti M, Sironi L, Cannata L et al. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil. Steril. 76(2), 235–240 (2001).
   PubMed Web of Science ®Google Scholar
• Raisz LG, Wiita B, Artis A et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J. Clin. Endocrinol. Metab. 81(1), 37–43 (1996).
   PubMed Web of Science ®Google Scholar
• Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom. Med. 47(4), 339–351 (1985).
   PubMed Web of Science ®Google Scholar
• Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology 10(3), 325–335 (1985).
   PubMed Web of Science ®Google Scholar
• Shifren JL, Davis SR, Moreau M et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 13(5), 770–779 (2006).
   PubMed Web of Science ®Google Scholar
• Warnock JK, Swanson SG, Borel RW, Zipfel LM, Brennan JJ; ESTRATEST Clinical Study Group. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. Menopause 12(4), 374–384 (2005).
   PubMed Web of Science ®Google Scholar
• Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet. Gynecol. 85(4), 529–537 (1995).
   PubMed Web of Science ®Google Scholar
• Zang H, Carlström K, Arner P, Hirschberg AL. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil. Steril. 86(1), 136–144 (2006).
   PubMed Web of Science ®Google Scholar
• Arrington R, Cofrancesco J, Wu AW. Questionnaires to measure sexual quality of life. Qual. Life Res. 13(10), 1643–1658 (2004).
   PubMed Web of Science ®Google Scholar
• Benetti-Pinto CL, Bedone AJ, Magna LA. Evaluation of serum androgen levels in women with premature ovarian failure. Fertil. Steril. 83(2), 508–510 (2005).
   PubMed Web of Science ®Google Scholar
• Bachelot A, Meduri G, Massin N, Misrahi M, Kuttenn F, Touraine P. Ovarian steroidogenesis and serum androgen levels in patients with premature ovarian failure. J. Clin. Endocrinol. Metab. 90(4), 2391–2396 (2005).
   PubMed Web of Science ®Google Scholar
• Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in Turner syndrome: a pilot study. J. Clin. Endocrinol. Metab. 94(12), 4820–4827 (2009).
   PubMed Web of Science ®Google Scholar
• Hahner S, Loeffler M, Fassnacht M et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92(10), 3912–3922 (2007).
   PubMed Web of Science ®Google Scholar
• Erichsen MM, Løvås K, Skinningsrud B et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab. 94(12), 4882–4890 (2009).
   PubMed Web of Science ®Google Scholar
• Jakobi JM, Killinger DW, Wolfe BM, Mahon JL, Rice CL. Quadriceps muscle function and fatigue in women with Addison’s disease. Muscle Nerve 24(8), 1040–1049 (2001).
   PubMed Web of Science ®Google Scholar
• Arlt W, Callies F, van Vlijmen JC et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. 341(14), 1013–1020 (1999).
   PubMed Web of Science ®Google Scholar
• Callies F, Fassnacht M, van Vlijmen JC et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J. Clin. Endocrinol. Metab. 86(5), 1968–1972 (2001).
   PubMed Web of Science ®Google Scholar
• Bilger M, Speraw S, LaFranchi SH, Hanna CE. Androgen replacement in adolescents and young women with hypopituitarism. J. Pediatr. Endocrinol. Metab. 18(4), 355–362 (2005).
   PubMed Web of Science ®Google Scholar
• Brooke AM, Kalingag LA, Miraki-Moud F et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J. Clin. Endocrinol. Metab. 91(10), 3773–3779 (2006).
   PubMed Web of Science ®Google Scholar
• Hunt PJ, Gurnell EM, Huppert FA et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. 85(12), 4650–4656 (2000).
   PubMed Web of Science ®Google Scholar
• Johannsson G, Burman P, Wirén L et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J. Clin. Endocrinol. Metab. 87(5), 2046–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Libè R, Barbetta L, Dall’Asta C et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J. Endocrinol. Invest. 27(8), 736–741 (2004).
   PubMed Web of Science ®Google Scholar
• Løvås K, Husebye ES. Replacement therapy in Addison’s disease. Expert Opin. Pharmacother. 4(12), 2145–2149 (2003).
   PubMed Web of Science ®Google Scholar
• Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 54(3), 765–769 (2005).
   PubMed Web of Science ®Google Scholar
• Dhatariya KK, Greenlund LJ, Bigelow ML et al. Dehydroepiandrosterone replacement therapy in hypoadrenal women: protein anabolism and skeletal muscle function. Mayo Clin. Proc. 83(11), 1218–1225 (2008).
   PubMed Web of Science ®Google Scholar
• Gurnell EM, Hunt PJ, Curran SE et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 93(2), 400–409 (2008).
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Romijn JA, Pereira AM et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. J. Clin. Endocrinol. Metab. 90(6), 3295–3303 (2005).
   PubMed Web of Science ®Google Scholar
• Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab. 82(10), 3498–3505 (1997).
   PubMed Web of Science ®Google Scholar
• Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas 63(3), 240–245 (2009).
   PubMed Web of Science ®Google Scholar
• Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J. Clin. Endocrinol. Metab. 96(6), 1642–1653 (2011).
   PubMed Web of Science ®Google Scholar
• Panjari M, Davis SR. DHEA for postmenopausal women: a review of the evidence. Maturitas 66(2), 172–179 (2010).
   PubMed Web of Science ®Google Scholar
• Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 78(6), 1360–1367 (1994).
   PubMed Web of Science ®Google Scholar
• Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Dehydroepiandrosterone replacement in aging humans. J. Clin. Endocrinol. Metab. 84(5), 1527–1533 (1999).
   PubMed Web of Science ®Google Scholar
• Baulieu EE, Thomas G, Legrain S et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl. Acad. Sci. USA 97(8), 4279–4284 (2000).
   PubMed Web of Science ®Google Scholar
• Nair KS, Rizza RA, O’Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. N. Engl. J. Med. 355, 1647–1659 (2006).
   PubMed Web of Science ®Google Scholar
• Arlt W. Dehydroepiandrosterone replacement therapy. Semin. Reprod. Med. 22(4), 379–388 (2004).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8(3), 181–187 (1999).
   PubMed Web of Science ®Google Scholar
• Hazeldine J, Arlt W, Lord JM. Dehydroepiandrosterone as a regulator of immune cell function. J. Steroid Biochem. Mol. Biol. 120(2–3), 127–136 (2010).
   PubMed Web of Science ®Google Scholar
• Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepi-androsterone supplementation augments ovarian stimulation in poor responders: a case series. Hum. Reprod. 15(10), 2129–2132 (2000).
   PubMed Web of Science ®Google Scholar
• Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil. Steril. 84(3), 756 (2005).
   PubMed Web of Science ®Google Scholar
• Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum. Reprod. 21(11), 2845–2849 (2006).
   PubMed Web of Science ®Google Scholar
• Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 25(10), 2496–2500 (2010).
   PubMed Web of Science ®Google Scholar
• Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod. Biomed. Online 21(3), 360–365 (2010).
   PubMed Web of Science ®Google Scholar
• Sunkara SK, Coomarasamy A. Androgen pretreatment in poor responders undergoing controlled ovarian stimulation and in vitro fertilization treatment. Fertil. Steril. 95(8), e73–e74; author reply e75 (2011).
   Google Scholar
• Gleicher N, Barad DH. Dehydroepi-androsterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 17(9), 67 (2011).
   Google Scholar
• Davis S. Testosterone deficiency in women. J. Reprod. Med. 46(Suppl. 3), 291–296 (2001).
   PubMed Web of Science ®Google Scholar
• Arlt W, Haas J, Callies F et al. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J. Clin. Endocrinol. Metab. 84(6), 2170–2176 (1999).
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Wang C, Cunningham G et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. 85(12), 4500–4510 (2000).
   PubMed Web of Science ®Google Scholar
• Buckler HM, Robertson WR, Wu FC. Which androgen replacement therapy for women? J. Clin. Endocrinol. Metab. 83(11), 3920–3924 (1998).
   PubMed Web of Science ®Google Scholar
• Singh AB, Lee ML, Sinha-Hikim I et al. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 91(1), 136–144 (2006).
   PubMed Web of Science ®Google Scholar
• Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol. Endocrinol. 27(1), 39–48 (2011).
   PubMed Web of Science ®Google Scholar
• Schover LR. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? Fertil. Steril. 90(1), 129–140 (2008).
   PubMed Web of Science ®Google Scholar
• Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 94(8), 606–616 (2002).
   PubMed Web of Science ®Google Scholar
• Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv. Exp. Med. Biol. 630, 148–165 (2008).
   PubMed Web of Science ®Google Scholar
• Kaaks R, Rinaldi S, Key TJ et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr. Relat. Cancer 12(4), 1071–1082 (2005).
   PubMed Web of Science ®Google Scholar
• Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl. Cancer Inst. 96(24), 1856–1865 (2004).
   PubMed Web of Science ®Google Scholar
• Zeleniuch-Jacquotte A, Shore RE, Koenig KL et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br. J. Cancer 90(1), 153–159 (2004).
   PubMed Web of Science ®Google Scholar
• Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch. Intern. Med. 166(14), 1483–1489 (2006).
   PubMed Web of Science ®Google Scholar
• Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch. Intern. Med. 169(1), 41–46 (2009).
   PubMed Web of Science ®Google Scholar
• Danforth KN, Eliassen AH, Tworoger SS et al. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int. J. Cancer 126(1), 199–207 (2010).
   PubMed Web of Science ®Google Scholar
• Davis SR, Hirschberg AL, Wagner LK, Lodhi I, von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J. Clin. Endocrinol. Metab. 94(12), 4907–4913 (2009).
   PubMed Web of Science ®Google Scholar
• McCormack VA, Dowsett M, Folkerd E et al. Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res. 11(3), R38 (2009).
   Google Scholar
• Helzlsouer KJ, Alberg AJ, Gordon GB et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274(24), 1926–1930 (1995).
   PubMed Web of Science ®Google Scholar
• Lukanova A, Lundin E, Akhmedkhanov A et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int. J. Cancer 104(5), 636–642 (2003).
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Dossus L, Lukanova A et al. Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol. Biomarkers Prev. 16(1), 23–29 (2007).
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Lee IM, Buring JE, Hankinson SE. Plasma androgen concentrations and risk of incident ovarian cancer. Am. J. Epidemiol. 167(2), 211–218 (2008).
   PubMed Web of Science ®Google Scholar
• Li AJ, Karlan BY. Androgens and epithelial ovarian cancer: What’s the connection? Cancer Biol. Ther. 7(11), 1712–1716 (2008).
   PubMed Web of Science ®Google Scholar
• Allen NE, Key TJ, Dossus L et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer 15(2), 485–497 (2008).
   PubMed Web of Science ®Google Scholar
• Bernini GP, Sgro’ M, Moretti A et al. Endogenous androgens and carotid intimal-medial thickness in women. J. Clin. Endocrinol. Metab. 84(6), 2008–2012 (1999).
   PubMed Web of Science ®Google Scholar
• Kiechl S, Willeit J, Bonora E, Schwarz S, Xu Q. No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study). Arterioscler. Thromb. Vasc. Biol. 20(4), 1094–1100 (2000).
   PubMed Web of Science ®Google Scholar
• Bernini GP, Moretti A, Sgró M et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 8(1), 43–50 (2001).
   PubMed Web of Science ®Google Scholar
• Golden SH, Maguire A, Ding J et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case–control study of the atherosclerosis risk in communities cohort. Am. J. Epidemiol. 155(5), 437–445 (2002).
   PubMed Web of Science ®Google Scholar
• Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur. J. Endocrinol. 156(6), 687–693 (2007).
   PubMed Web of Science ®Google Scholar
• Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutr. Metab. Cardiovasc. Dis. 17(10), 705–711 (2007).
   PubMed Web of Science ®Google Scholar
• Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J. Clin. Endocrinol. Metab. 93(1), 131–138 (2008).
   PubMed Web of Science ®Google Scholar
• Mudali S, Dobs AS, Ding J, Cauley JA, Szklo M, Golden SH; atherosclerosis risk in communities study. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J. Clin. Endocrinol. Metab. 90(2), 1202–1209 (2005).
   PubMed Web of Science ®Google Scholar
• Lambrinoudaki I, Christodoulakos G, Rizos D et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur. J. Endocrinol. 154(6), 907–916 (2006).
   PubMed Web of Science ®Google Scholar
• Manolakou P, Angelopoulou R, Bakoyiannis C, Bastounis E. The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression. Reprod. Biol. Endocrinol. 7, 44 (2009).
   PubMedGoogle Scholar
• Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J. Sex. Med. 7(1 Pt 2), 314–326 (2010).
   PubMed Web of Science ®Google Scholar